Personalized medicine. Closing the gap between knowledge and clinical practice

被引:39
作者
Anaya, Juan-Manuel [1 ]
Duarte-Rey, Carolina [1 ]
Sarmiento-Monroy, Juan C. [1 ]
Bardey, David [2 ,3 ]
Castiblanco, John [1 ,4 ]
Rojas-Villarraga, Adriana [1 ]
机构
[1] Univ Rosario, Sch Med & Hlth Sci, Ctr Autoimmune Dis Res CREA, Carrera 26 63B-51, Bogota 111221, Colombia
[2] Univ Los Andes, Fac Econ Cede, Bogota, Colombia
[3] Toulouse Sch Econ, Toulouse, France
[4] Univ Rosario, Doctoral Program Biomed Sci, Bogota 111221, Colombia
关键词
Precision medicine; Pharmacogenomics; Autoimmune ecology; Rheumatoid arthritis; Type; 1; diabetes; Developing countries; PRIMARY BILIARY-CIRRHOSIS; ANTITUMOR NECROSIS FACTOR; TYPE-1; DIABETES-MELLITUS; LATIN-AMERICAN PATIENTS; RHEUMATOID-ARTHRITIS; VITAMIN-D; AUTOIMMUNE-DISEASES; PRIMARY PREVENTION; ADALIMUMAB TREATMENT; BRITISH-SOCIETY;
D O I
10.1016/j.autrev.2016.06.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Personalized medicine encompasses a broad and evolving field informed by a patient distinctive information and biomarker profile. Although terminology is evolving and some semantic interpretations exist (e.g., personalized, individualized, precision), in a broad sense personalized medicine can be coined as: "To practice medicine as it once used to be in the past using the current biotechnological tools." A humanized approach to personalized medicine would offer the possibility of exploiting systems biology and its concept of P5 medicine, where predictive factors for developing a disease should be examined within populations in order to establish preventive measures on at-risk individuals, for whom healthcare should be personalized and participatory. Herein, the process of personalized medicine is presented together with the options that can be offered in health care systems with limited resources for diseases like rheumatoid arthritis and type 1 diabetes. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:833 / 842
页数:10
相关论文
共 50 条
[31]   Personalized medicine and economic evaluation in oncology: all theory and no practice? [J].
Garattini, Livio ;
Curto, Alessandro ;
Freemantle, Nick .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (05) :733-738
[32]   The safety of early phase clinical trials: Bridging the gap between governance and practice [J].
Lorch, Ulrike ;
Vincent, Charles .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (07) :1538-1540
[33]   Closing Knowledge Gaps to Optimize Patient Outcomes and Advance Precision Medicine [J].
Giusti, Kathy ;
Young, Anne Quinn ;
Lehrhaupt, Kerri .
CANCER JOURNAL, 2018, 24 (03) :140-147
[34]   Translating Scientific Evidence Into Clinical Practice: Closing the Loop [J].
Godoy, Lucas C. ;
Farkouh, Michael E. .
CANADIAN JOURNAL OF CARDIOLOGY, 2020, 36 (08) :1191-1193
[35]   Assessing Patient Readiness for the Clinical Adoption of Personalized Medicine [J].
Issa, A. M. ;
Tufail, W. ;
Hutchinson, J. ;
Tenorio, J. ;
Baliga, M. Poonam .
PUBLIC HEALTH GENOMICS, 2009, 12 (03) :163-169
[36]   Personalized medicine: Clinical oncology on molecular view of treatment [J].
Da Silva, Rafick Costa Dos Santos ;
Simon, Nathalia de Andrade ;
Dos Santos, Andre Alves ;
Olegario, Gabriel De Melo ;
Da Silva, Jayne Ferreira ;
Sousa, Naide Oliveira ;
Corbacho, Manuel Alvarez Troncoso ;
de Melo, Fabricio Freire .
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2024, 15 (08)
[37]   Clinical pharmacology, biomarkers and personalized medicine: education please [J].
de Koning, Paul ;
Keirns, James .
BIOMARKERS IN MEDICINE, 2009, 3 (06) :685-700
[38]   Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines [J].
Tsung Yu ;
Daniela Vollenweider ;
Ravi Varadhan ;
Tianjing Li ;
Cynthia Boyd ;
Milo A Puhan .
BMC Medicine, 11
[39]   Gap between clinical trials and clinical practice - Lessons from the Bypass Angioplasty Revascularization Investigation (BARI) [J].
Frye, RL ;
Brooks, MM ;
Nesto, RW .
CIRCULATION, 2003, 107 (14) :1837-1839
[40]   Harnessing pharmacological knowledge for personalized medicine and pharmacotyping: Challenges and lessons learned [J].
Ioannis S Vizirianakis .
World Journal of Pharmacology, 2014, (04) :110-119